TAK, US8740602052

Takeda Pharmaceutical stock trades at EUR 16.55 with a P/ E of 52.1

Published on 10/09/2026 at 16:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Takeda Pharmaceutical stock costs EUR 16.55 on October 9, 2026 after EUR 16.55. Results are due October 29, 2026 and target is USD 22.00.

Key points in brief

Takeda Pharmaceutical stock was unchanged at EUR 16.55 at Lang & Schwarz on October 9, 2026.
The stock's market capitalization was USD 59.6 billion and its P/E ratio was 52.1.
Second-quarter results are scheduled for October 29, 2026.
Financhill listed a consensus 12-month target of USD 22.00 from three analysts.

TAK, US8740602052, Illustration mit AI erstellt.

TAK stood at EUR 16.55 at Lang & Schwarz on October 9, 2026 at 4:00 p.m. CEST, unchanged versus the prior close of EUR 16.55. The flat session leaves valuation and the October reporting date as the clearest market reference points.

Trading stays unchanged

The bid was EUR 16.00 and the ask was EUR 17.10 at the same Lang & Schwarz snapshot. The quote remained inside that EUR 1.10 spread, while the prior close was EUR 16.55 on October 8, 2026.

Trading volume stood at 246,557 shares on October 9, 2026, compared with an average volume of 3,037,078 shares. That places the session volume 91.88 percent below the average, indicating limited turnover at the quoted level.

Valuation and calendar

Takeda's market capitalization was USD 59.6 billion on October 9, 2026, and its P/E ratio was 52.1. The figures describe the U.S.-dollar quotation separately from the EUR price at Lang & Schwarz.

Simply Wall St identifies Takeda as TSE:4502 and lists October 29, 2026 as the next earnings date. The date gives investors a defined calendar point for the next update.

Financhill lists a consensus 12-month target of USD 22.00 from three analysts and a Buy consensus rating. That target is stated in U.S. dollars and is not converted into the EUR Lang & Schwarz quote.

Comparison with peers

Takeda: unchanged, P/E 52.1, market capitalization USD 59.6 billion

Johnson & Johnson (NYSE, USD): plus 1.0 percent, P/E 30.0, market capitalization USD 624.2 billion

Pfizer (NYSE, USD): plus 1.1 percent, P/E 37.2, market capitalization USD 160.3 billion

What the next date adds

October 29, 2026 is the next scheduled reporting date, while the current market snapshot places Takeda at EUR 16.55 and the P/E ratio at 52.1. The comparison with Johnson & Johnson and Pfizer highlights the different scale and valuation profiles within large pharmaceutical companies without combining currencies.

The further course of trading is shown by the continuously updated real-time quote of Takeda Pharmaceutical stock.